Novo Nordisk A/S $NVO
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS61
PHASE 3 / 2-350
RECRUITING27
READOUTS ≤12 MONTHS15
READOUT SLIPPED >6 MO36%
Delay Index: of 28 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.5 months). See all sponsors →
Open Novo Nordisk A/S on the live radar map → 📅 $NVO readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Somapacitan NCT03878446 |
P2 | Active, not recruiting | Short Stature Children Born Small for Gestational Age (SGA) | 62 | 2021-05-05 (+21 mo) |
| explorer7 NCT04083781 |
P3 | Active, not recruiting | Haemophilia A With Inhibitors; Haemophilia B With Inhibitors | 134 | 2021-12-27 (+14 mo) |
| explorer8 NCT04082429 |
P3 | Active, not recruiting | Haemophilia A Without Inhibitors; Haemophilia B Without Inhibitors | 156 | 2022-07-12 (+20 mo) |
| Liraglutide NCT04775082 |
P3 | Active, not recruiting | Obesity | 82 | 2023-08-01 |
| REAL 9 NCT05723835 |
P3 | Active, not recruiting | SGA; Turner Syndrome | 47 | 2024-06-07 (-2 mo) |
| REAL 8 NCT05330325 |
P3 | Active, not recruiting | SGA, Turner Syndrome, Noonan Syndrome, ISS | 412 | 2024-08-05 |
| REDEFINE 1 NCT05567796 |
P3 | Active, not recruiting | Obesity | 3400 | 2024-10-30 (-3 mo) |
| STEP Young NCT05726227 |
P3 | Active, not recruiting | Obesity | 212 | 2025-10-15 |
| Explorer10 NCT05135559 |
P3 | Active, not recruiting | Haemophilia A and B With and Without Inhibitors | 153 | 2026-04-21 (+17 mo) |
| NNC0519-0130 NCT06717698 |
P2 | Recruiting | Chronic Kidney Disease | 465 | 2026-09-01 (+13 mo) |
| ATHENA NCT06200207 |
P3 | Active, not recruiting | Heart Failure; Systemic Inflammation | 673 | 2026-10-01 (+5 mo) |
| NNC0662-0419 NCT07184632 |
P2 | Active, not recruiting | Overweight; Obesity | 224 | 2026-12-14 |
| UBT251 NCT07395687 |
P2 | Recruiting | Overweight; Obesity | 333 | 2027-01-14 |
| ONWARDS 11 NCT07076199 |
P3 | Active, not recruiting | Diabetes Mellitus, Type 1 | 877 | 2027-01-25 (+2 mo) |
| ARTEMIS NCT06118281 |
P3 | Active, not recruiting | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | 10000 | 2027-01-29 (+5 mo) |
| CagriSema (Cagrilintide B and Semaglutide I) NCT07011667 |
P3 | Active, not recruiting | Obesity | 609 | 2027-03-01 (+2 mo) |
| RENEW 1 NCT07220642 |
P3 | Active, not recruiting | Obesity; Overweight | 300 | 2027-05-11 |
| RENEW 2 NCT07220759 |
P3 | Active, not recruiting | Overweight; Obesity | 330 | 2027-05-12 |
| 8282-Reduced NCT06979375 |
P2 | Recruiting | Heart Failure | 200 | 2027-05-16 |
| RENEW 4 NCT07745504 |
P3 | Recruiting | Overweight; Obesity | 285 | 2027-05-18 |
| CagriSema NCT07817251 |
P3 | Recruiting | Diabetes Mellitus, Type 2 | 210 | 2027-06-09 |
| NNC0662-0419 NCT07639021 |
P2 | Active, not recruiting | Obesity | 233 | 2027-06-14 |
| Hibiscus 2 NCT06612268 |
P3 | Recruiting | Sickle Cell Disease | 510 | 2027-08-27 (+20 mo) |
| REDEFINE 3 NCT05669755 |
P3 | Active, not recruiting | Cardiovascular Disease | 7101 | 2027-09-01 (+4 mo) |
| NNC0662-0419 NCT07415954 |
P2 | Recruiting | Diabetes Mellitus, Type 2 | 270 | 2027-09-03 |
| UBT251 NCT07668388 |
P2 | Recruiting | Diabetes Mellitus, Type 2 | 300 | 2027-10-04 |
| FOCUS NCT03811561 |
P3 | Active, not recruiting | Diabetes Mellitus, Type 2 | 1500 | 2027-11-07 (+33 mo) |
| 8212-Preserved NCT06979362 |
P2 | Recruiting | Heart Failure | 200 | 2027-11-16 (+6 mo) |
| OASIS 5 NCT07770841 |
P3 | Recruiting | Overweight; Obesity | 450 | 2028-02-22 |
| Cagrisema NCT07564414 |
P3 | Recruiting | Obesity; Type 2 Diabetes | 2500 | 2028-02-23 |
| NNC6019-0001 NCT06260709 |
P2 | Active, not recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | 88 | 2028-02-29 |
| NNC0662-3168 (Test product-A) NCT07940803 |
P1/2 | Not yet recruiting | Overweight; Obesity | 300 | 2028-03-25 |
| REDEFINE NCT07919405 |
P3 | Not yet recruiting | Hypertension; Obesity | 1408 | 2028-06-01 |
| AMBITION 1 NCT07931495 |
P3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 200 | 2028-06-05 |
| AMAZE 12 NCT07503210 |
P3 | Active, not recruiting | Obesity | 606 | 2028-06-06 |
| AMAZE 4 NCT07571109 |
P3 | Recruiting | Obesity; Overweight | 300 | 2028-06-26 |
| AMAZE 9 NCT07720271 |
P3 | Recruiting | Overweight; Obesity | 950 | 2028-06-27 |
| FRONTIER4 NCT05685238 |
P3 | Active, not recruiting | Haemophilia A; Haemophilia A With Inhibitors | 451 | 2028-06-30 (+2 mo) |
| AMBITION 3 NCT07931573 |
P3 | Not yet recruiting | Type 2 Diabetes | 1200 | 2028-07-04 |
| AMAZE 3 NCT07571005 |
P3 | Recruiting | Obesity; Overweight | 300 | 2028-07-12 |
| AMBITION4 NCT07931599 |
P3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1060 | 2028-07-24 |
| AMBITION 7 NCT07797335 |
P3 | Recruiting | Type 2 Diabetes; Cardiovascular Risk | 1778 | 2028-07-31 |
| AMBITION 2 NCT07931547 |
P3 | Not yet recruiting | Type 2 Diabetes; Chronic Kidney Disease | 450 | 2028-07-31 |
| AMAZE 2 NCT07533175 |
P3 | Active, not recruiting | Diabetes Mellitus; Overweight | 638 | 2028-08-07 |
| AMAZE 5 NCT07481630 |
P3 | Recruiting | Obesity; Knee Osteoarthritis (OA) | 400 | 2028-08-14 |
| AMAZE 6 NCT07509307 |
P3 | Recruiting | Obesity; Overweight | 400 | 2028-08-14 |
| Cagrilintide NCT06780449 |
P3 | Active, not recruiting | Obesity | 400 | 2028-08-28 |
| AMAZE 7 NCT07668414 |
P3 | Recruiting | Overweight; Obesity | 650 | 2028-10-10 |
| ZEPHYR NCT07301034 |
P3 | Recruiting | Myocardial Infarction | 332 | 2028-11-14 |
| AMAZE 8 NCT07400107 |
P3 | Active, not recruiting | Obesity; Overweight | 985 | 2028-12-19 |
| AMAZE 13 NCT07668401 |
P3 | Not yet recruiting | Obesity; Overweight | 400 | 2029-01-11 |
| AMAZE 10 NCT07822061 |
P3 | Recruiting | Overweight; Obesity | 400 | 2029-02-05 |
| FRONTIERAHA NCT07830732 |
P3 | Recruiting | Haemophilia A | 84 | 2029-03-23 |
| ESSENCE NCT04822181 |
P3 | Active, not recruiting | Non-alcoholic Steatohepatitis | 1205 | 2029-04-25 (+13 mo) |
| AMAZE 1 NCT07339423 |
P3 | Recruiting | Obesity | 1150 | 2029-06-26 |
| CLEOPATTRA NCT07207811 |
P3 | Recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | 1280 | 2029-06-29 |
| HF-POLARIS NCT07567001 |
P3 | Recruiting | Obesity; Heart Failure | 5610 | 2029-07-23 |
| REIMAGINEYOUNG NCT07282613 |
P3 | Recruiting | Diabetes Mellitus, Type 2 | 80 | 2029-09-07 |
| Cagrilintide NCT07253285 |
P3 | Recruiting | Overweight; Obesity | 460 | 2030-03-20 |
| AMBIENCE NCT07861100 |
P3 | Not yet recruiting | Cardiovascular Risk; Obesity | 8500 | 2030-09-16 |
| FLORAL NCT06609226 |
P3 | Recruiting | Sickle Cell Disease; Thalassemia | 480 | 2030-12-30 (+13 mo) |